Research Papers

This database includes peer-reviewed publications authored or funded by TB Alliance. Use the tags on the right to filter by subject, or search for a particular author or term using the search bar.

Displaying 174 papers

Keeping the Promise: Product Development Partnerships’ Role in the New Age of Health Research and Product Development:

1/2021

Tags: TB Drug Market

Phase 1 Study of the Effects of the Investigational Tuberculosis Treatment Pretomanid, Alone and in Combination with Moxifloxacin, on the QTc Interval in Healthy Volunteers

12/2020

Author(s): Mengchun Li , George A Saviolakis , Wael El-Amin , Mamodikoe K Makhene , Blaire Osborn , Jerry Nedelman , Tian J Yang , Daniel Everitt

Tags: Clinical Trial Results, Moxifloxacin, Pretomanid/PA-824

Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis

12/2020

Author(s): Dalin Rifat , Si-Yang Li , Thomas Ioerger , Keshav Shah , Jean-Philippe Lanoix , Jin Lee , Ghader Bashiri , James Sacchettini , Eric Nuermberger

Tags: M.tb. Biology, Pretomanid/PA-824

The Clinical Dose of Pretomanid: An Exposure-Response Perspective

12/2020

Author(s): Jerry R. Nedelman, David H. Salinger, Vishak Subramoney, Rob Woolson, Karen Wade, Mengchun Li, Daniel Everitt, Carl M. Mendel, Mel Spigelman

Tags: BPaL, Clinical Development, Nix-TB, Pretomanid/PA-824

Clofazimine pharmacokinetics in patients with TB: dosing implications

8/2020

Author(s): Mahmoud Tareq Abdelwahab, Sean Wasserman, James C M Brust, Neel R Gandhi, Graeme Meintjes, Daniel Everitt, Andreas Diacon, Rodney Dawson, Lubbe Wiesner, Elin M Svensson, Gary Maartens, Paolo Denti

Tags: Clofazamine, Pharmacokinetics

No antimicrobial resistance research agenda without tuberculosis

8/2020 - The Lancet Global Health

Author(s): Gwenan M Knight, Mario C Raviglione, *Richard G White

Tags: MDR-TB, XDR-TB

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

3/2020 - The New England Journal of Medicine

Author(s): Francesca Conradie, M.B., B.Ch., Andreas H. Diacon, M.D., Nosipho Ngubane, M.B., B.Ch., Pauline Howell, M.B., B.Ch., Daniel Everitt, M.D., Angela M. Crook, Ph.D., Carl M. Mendel, M.D., Erica Egizi, M.P.H., et al., for the Nix-TB Trial Team*

Tags: Bedaquiline (TMC-207), BPaL, Clinical Trial Results, Linezolid, MDR-TB, Pretomanid/PA-824, Regimen Change, Trial Design, XDR-TB

Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis

1/2020 - Antimicrobial Agents and Chemotherapy

Author(s): Andreas H. Diacon, Veronique R. De Jager, Rodney Dawson, Kim Narunsky, Naadira Vanker, Divan A. Burger, Daniel Everitt, Frances Pappas, Jerry Nedelman, Carl M. Mendel

Tags: Drug-Sensitivity Testing, Linezolid, Pharmacokinetics

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

11/2019 - The Lancet Respiratory Medicine

Author(s): Conor D Tweed, Rodney Dawson, Divan A Burger, Almari Conradie, Angela M Crook, Carl M Mendel, Francesca Conradie, Andreas H Diacon, Nyanda E Ntinginya, Daniel E Everitt, Frederick Haraka, Mengchun Li, Christo H van Niekerk, Alphonse Okwera

Tags: Bedaquiline (TMC-207), BPaZ, Clinical Trial Results, MDR-TB, Moxifloxacin, NC-005, PaMZ, Pretomanid/PA-824, Trial Design

Daily Dosing for Bedaquiline in Patients with Tuberculosis

10/2019 - Antimicrobial Agents and Chemotheraphy

Author(s): Salinger DH, Nedelman JR, Mendel C, Spigelman M, Hermann

Tags: Bedaquiline (TMC-207), BPaL

Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations

9/2019 - BMC Infectious Diseases

Author(s): Emily A. Kendall, Shelly Malhotra, Sarah Cook-Scalise, Claudia M. Denkinger, David W. Dowdy

Tags: Bedaquiline (TMC-207), Moxifloxacin, Pyrazinamide, Regimen Change

Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

8/2019 - BMC Pulmonary Medicine

Author(s): Conor D. Tweed, Angela M. Crook, Rodney Dawson, Andreas H. Diacon, Timothy D. McHugh, Carl M. Mendel, Sarah K. Meredith, Lerato Mohapi, Michael E. Murphy, Andrew J. Nunn, Patrick P. J. Phillips, Kasha P. Singh, Melvin Spigelman, Stephen H. Gillespie

Tags: Clinical Trial Results, ReMoxTB

Population Pharmacokinetics of the Antituberculosis Agent Pretomanid

8/2019 - Antimicrobial Agents and Chemotheraphy

Author(s): David H. Salinger, Vishak Subramoney, Daniel Everitt, Jerry R. Nedelman

Tags: BPaL, Pharmacokinetics, Pretomanid/PA-824

Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis

7/2019 - Antimicrobial Agents and Chemotheraphy

Author(s): Hanbin Li, David H. Salinger, Daniel Everitt, Mengchun Li, Angelo Del Parigi, Carl Mendel, Jerry R. Nedelman

Tags: BPaL, Pharmacodynamics, Pretomanid/PA-824

Antibacterial Activity of Coastal Plants and Marine Sponges from Kei Island Indonesia against Bacterial Fish Pathogens

7/2019 - Pharmacognosy Journal

Author(s): Andi Hamdillah, Alim Isnansetyo, Indah Istiqomah, Indun Dewi Puspita, Desy Putri Handayani, Takushi Kaneko

Tags: Drug Discovery

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis

4/2019 - Antimicrobial Agents and Chemotheraphy

Author(s): Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton, Mdluli, Fotouhi, Nuermberger EL

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Moxifloxacin, Pretomanid/PA-824, Pyrazinamide

An Assessment of Global Chemistry, Manufacturing and Controls (CMC) Regulatory Requirements in Low and Middle Income Countries

11/2018 - WHO Drugs Journal

Author(s): Rajneesh Taneja, Christine Chacko, Kedar Gumaste, Subina Surendran, Arturo Olguin Pelayo, Adrienne VidalIrizarry, Diana Elkis, Arran Basra, Myrto Lee, Robert Franco

Tags: Advocacy, TB Market, TB-HIV

Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMox TB study

10/2018 - BMC Medicine (2018) 16:189

Author(s): Murphy, M.; Wills, G; Murthy, S.; Louw, C.; Bateson, A.; Hunt, R.; McHugh, T.; Nunn, A.; Meredith, S.; Mendel, C.; Spigelman, M.; Crook, A.; Gillespie, S.

Tags: ReMoxTB

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

7/2018 - BMC Infectious Diseases

Author(s): Tweed, Conor D., Crook, Angela M. Amukoye, Evans I. Dawson, Rodney Diacon, Andreas H. Hanekom, Madeline McHugh, Timothy D. Mendel, Carl M. Meredith, Sarah K. Murphy, Michael E. Murthy, Saraswathi E. Nunn, Andrew, Spigelman, M.

Tags: Clinical Trial Results, ReMoxTB

Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis.

5/2018 - BMC Medicine

Author(s): Murthy S., Chatterjee F., Crook A., Dawson R., Mendel C., Murphy M., Murray S., Nunn A., Phillips P., Singh K., McHugh T., Gillespie S.

Tags: ReMoxTB

Pages